Grants and Contributions:
Title:
COVID-19-Treatment for lung injury
Agreement Number:
966019
Agreement Value:
$2,282,176.00
Agreement Date:
Feb 1, 2021 - May 31, 2023
Description:
FB100 is a novel treatment for COVID-19 survivors with lung fibrosis. This project will focus on providing preclinical proof-of concept results showing antifibrotic efficacy and tolerability in relevant animal models. In addition, the project will allow HyperMabs to initiate critical manufacturing work that will support the preclinical studies a well as product characterization and release. This project represents important steps of the full non-clinical FB100 development program which will lead to clinical trials in early 2022.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5L 1A9
Reference Number:
172-2020-2021-Q4-966019
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
704342872
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Amendment Date
Dec 8, 2022
Recipient's Legal Name:
HyperMabs Inc.
Federal Riding Name:
Toronto Centre
Federal Riding Number:
35108
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: